| James K Mcphelan Od Pc | |
|
16429 N Tatum Blvd, Phoenix, AZ 85032-3458 | |
| (480) 889-6044 | |
| Not Available |
| Full Name | James K Mcphelan Od Pc |
|---|---|
| Type | Facility |
| Speciality | Optometrist |
| Location | 16429 N Tatum Blvd, Phoenix, Arizona |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043485840 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 1020 (Arizona) | Primary |
| Provider Name | Bryan L Fuller |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1285682146 PECOS PAC ID: 4183794704 Enrollment ID: I20080609000097 |
News Archive
BioCryst Pharmaceuticals, Inc. announced preliminary top-line results from its multinational, open-label, single-arm trial evaluating 200 mg once-daily oral forodesine in the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL), as well as interim results from the Company's exploratory Phase 2 study to investigate the efficacy and safety of 200 mg twice-daily oral forodesine as monotherapy for chronic lymphocytic leukemia (CLL).
As a researcher in neurogastroenterology for 40 years, professor Khalil Bitar has spent his professional life studying the causes of perplexing and what frequently become embarrassing problems for humans—issues such as constipation, diarrhea and colon disease.
If you believe you are capable of becoming the healthy, engaged person you want to be in old age, you are much more likely to experience that outcome, a recent Oregon State University study shows.
Projects and programs to combat childhood obesity have made great strides in health and behavior, yet the epidemic persists. Indeed, First Lady Michelle Obama's "Let's Move" initiative has made the issue of childhood obesity a focal point and national priority.
A University of Greenwich lecturer's book could be the blueprint to produce a generation of super gymnasts.
› Verified 4 days ago
| Provider Name | James K Mcphelan |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1437107307 PECOS PAC ID: 4587739206 Enrollment ID: I20080814000592 |
News Archive
BioCryst Pharmaceuticals, Inc. announced preliminary top-line results from its multinational, open-label, single-arm trial evaluating 200 mg once-daily oral forodesine in the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL), as well as interim results from the Company's exploratory Phase 2 study to investigate the efficacy and safety of 200 mg twice-daily oral forodesine as monotherapy for chronic lymphocytic leukemia (CLL).
As a researcher in neurogastroenterology for 40 years, professor Khalil Bitar has spent his professional life studying the causes of perplexing and what frequently become embarrassing problems for humans—issues such as constipation, diarrhea and colon disease.
If you believe you are capable of becoming the healthy, engaged person you want to be in old age, you are much more likely to experience that outcome, a recent Oregon State University study shows.
Projects and programs to combat childhood obesity have made great strides in health and behavior, yet the epidemic persists. Indeed, First Lady Michelle Obama's "Let's Move" initiative has made the issue of childhood obesity a focal point and national priority.
A University of Greenwich lecturer's book could be the blueprint to produce a generation of super gymnasts.
› Verified 4 days ago
| Provider Name | Kenneth W O'daniel |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1942269659 PECOS PAC ID: 7012805997 Enrollment ID: I20101110000192 |
News Archive
BioCryst Pharmaceuticals, Inc. announced preliminary top-line results from its multinational, open-label, single-arm trial evaluating 200 mg once-daily oral forodesine in the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL), as well as interim results from the Company's exploratory Phase 2 study to investigate the efficacy and safety of 200 mg twice-daily oral forodesine as monotherapy for chronic lymphocytic leukemia (CLL).
As a researcher in neurogastroenterology for 40 years, professor Khalil Bitar has spent his professional life studying the causes of perplexing and what frequently become embarrassing problems for humans—issues such as constipation, diarrhea and colon disease.
If you believe you are capable of becoming the healthy, engaged person you want to be in old age, you are much more likely to experience that outcome, a recent Oregon State University study shows.
Projects and programs to combat childhood obesity have made great strides in health and behavior, yet the epidemic persists. Indeed, First Lady Michelle Obama's "Let's Move" initiative has made the issue of childhood obesity a focal point and national priority.
A University of Greenwich lecturer's book could be the blueprint to produce a generation of super gymnasts.
› Verified 4 days ago
| Provider Name | Christina M Wong |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1568743250 PECOS PAC ID: 5496928731 Enrollment ID: I20111101000428 |
News Archive
BioCryst Pharmaceuticals, Inc. announced preliminary top-line results from its multinational, open-label, single-arm trial evaluating 200 mg once-daily oral forodesine in the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL), as well as interim results from the Company's exploratory Phase 2 study to investigate the efficacy and safety of 200 mg twice-daily oral forodesine as monotherapy for chronic lymphocytic leukemia (CLL).
As a researcher in neurogastroenterology for 40 years, professor Khalil Bitar has spent his professional life studying the causes of perplexing and what frequently become embarrassing problems for humans—issues such as constipation, diarrhea and colon disease.
If you believe you are capable of becoming the healthy, engaged person you want to be in old age, you are much more likely to experience that outcome, a recent Oregon State University study shows.
Projects and programs to combat childhood obesity have made great strides in health and behavior, yet the epidemic persists. Indeed, First Lady Michelle Obama's "Let's Move" initiative has made the issue of childhood obesity a focal point and national priority.
A University of Greenwich lecturer's book could be the blueprint to produce a generation of super gymnasts.
› Verified 4 days ago
| Provider Name | Bessie Campouris |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1306286273 PECOS PAC ID: 2961646187 Enrollment ID: I20130910000168 |
News Archive
BioCryst Pharmaceuticals, Inc. announced preliminary top-line results from its multinational, open-label, single-arm trial evaluating 200 mg once-daily oral forodesine in the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL), as well as interim results from the Company's exploratory Phase 2 study to investigate the efficacy and safety of 200 mg twice-daily oral forodesine as monotherapy for chronic lymphocytic leukemia (CLL).
As a researcher in neurogastroenterology for 40 years, professor Khalil Bitar has spent his professional life studying the causes of perplexing and what frequently become embarrassing problems for humans—issues such as constipation, diarrhea and colon disease.
If you believe you are capable of becoming the healthy, engaged person you want to be in old age, you are much more likely to experience that outcome, a recent Oregon State University study shows.
Projects and programs to combat childhood obesity have made great strides in health and behavior, yet the epidemic persists. Indeed, First Lady Michelle Obama's "Let's Move" initiative has made the issue of childhood obesity a focal point and national priority.
A University of Greenwich lecturer's book could be the blueprint to produce a generation of super gymnasts.
› Verified 4 days ago
| Provider Name | Ryan Gregory Felten |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1407239254 PECOS PAC ID: 2769796184 Enrollment ID: I20150729009361 |
News Archive
BioCryst Pharmaceuticals, Inc. announced preliminary top-line results from its multinational, open-label, single-arm trial evaluating 200 mg once-daily oral forodesine in the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL), as well as interim results from the Company's exploratory Phase 2 study to investigate the efficacy and safety of 200 mg twice-daily oral forodesine as monotherapy for chronic lymphocytic leukemia (CLL).
As a researcher in neurogastroenterology for 40 years, professor Khalil Bitar has spent his professional life studying the causes of perplexing and what frequently become embarrassing problems for humans—issues such as constipation, diarrhea and colon disease.
If you believe you are capable of becoming the healthy, engaged person you want to be in old age, you are much more likely to experience that outcome, a recent Oregon State University study shows.
Projects and programs to combat childhood obesity have made great strides in health and behavior, yet the epidemic persists. Indeed, First Lady Michelle Obama's "Let's Move" initiative has made the issue of childhood obesity a focal point and national priority.
A University of Greenwich lecturer's book could be the blueprint to produce a generation of super gymnasts.
› Verified 4 days ago
| Provider Name | Megan Catherine Houle |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1518667476 PECOS PAC ID: 7517331846 Enrollment ID: I20230328000607 |
News Archive
BioCryst Pharmaceuticals, Inc. announced preliminary top-line results from its multinational, open-label, single-arm trial evaluating 200 mg once-daily oral forodesine in the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL), as well as interim results from the Company's exploratory Phase 2 study to investigate the efficacy and safety of 200 mg twice-daily oral forodesine as monotherapy for chronic lymphocytic leukemia (CLL).
As a researcher in neurogastroenterology for 40 years, professor Khalil Bitar has spent his professional life studying the causes of perplexing and what frequently become embarrassing problems for humans—issues such as constipation, diarrhea and colon disease.
If you believe you are capable of becoming the healthy, engaged person you want to be in old age, you are much more likely to experience that outcome, a recent Oregon State University study shows.
Projects and programs to combat childhood obesity have made great strides in health and behavior, yet the epidemic persists. Indeed, First Lady Michelle Obama's "Let's Move" initiative has made the issue of childhood obesity a focal point and national priority.
A University of Greenwich lecturer's book could be the blueprint to produce a generation of super gymnasts.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| James K Mcphelan Od Pc 16429 N Tatum Blvd, Phoenix, AZ 85032-3458 Ph: (480) 889-6044 | James K Mcphelan Od Pc 16429 N Tatum Blvd, Phoenix, AZ 85032-3458 Ph: (480) 889-6044 |
News Archive
BioCryst Pharmaceuticals, Inc. announced preliminary top-line results from its multinational, open-label, single-arm trial evaluating 200 mg once-daily oral forodesine in the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL), as well as interim results from the Company's exploratory Phase 2 study to investigate the efficacy and safety of 200 mg twice-daily oral forodesine as monotherapy for chronic lymphocytic leukemia (CLL).
As a researcher in neurogastroenterology for 40 years, professor Khalil Bitar has spent his professional life studying the causes of perplexing and what frequently become embarrassing problems for humans—issues such as constipation, diarrhea and colon disease.
If you believe you are capable of becoming the healthy, engaged person you want to be in old age, you are much more likely to experience that outcome, a recent Oregon State University study shows.
Projects and programs to combat childhood obesity have made great strides in health and behavior, yet the epidemic persists. Indeed, First Lady Michelle Obama's "Let's Move" initiative has made the issue of childhood obesity a focal point and national priority.
A University of Greenwich lecturer's book could be the blueprint to produce a generation of super gymnasts.
› Verified 4 days ago
Moon Valley Eyecare Optometrist Medicare: Medicare Enrolled Practice Location: 14435 N 7th St, Ste 104, Phoenix, AZ 85022 Phone: 602-993-2727 Fax: 602-449-0681 | |
Dr. Karly Baier, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 300 W Clarendon Ave Ste 150, Phoenix, AZ 85013 Phone: 602-283-4503 Fax: 844-965-9564 | |
Dr. Aleta Belinda Gong, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 16020 N 35th Ave, Phoenix, AZ 85053 Phone: 602-547-3255 | |
Optical Expressions Pllc Optometrist Medicare: Medicare Enrolled Practice Location: 112 W Mcdowell Rd, Phoenix, AZ 85003 Phone: 602-254-3169 Fax: 602-256-7112 | |
Suzanne Streff, O.d. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 9617 N Metro Pkwy W, 1000, Phoenix, AZ 85051 Phone: 602-678-4395 Fax: 602-678-4396 | |
Dr. Lois Filipelli, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: Abc Children's Eye Specialists, 1010 E Mcdowell Rd, Ste 301, Phoenix, AZ 85006 Phone: 602-222-2234 | |
Dr. Peter Rosenberg, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 3415 W Glendale Ave, Building B, Suite 11, Phoenix, AZ 85051 Phone: 602-973-5868 Fax: 602-973-6076 |